The impact of brain disorders like Alzheimer's and autism spectrum disorder on a patient's brain function will soon be visible to researchers in real time. They will then be able to create more potent treatments to treat the more than 10 million Americans who currently suffer from these still-mysterious ailments thanks to that window into the brain.
New positron emission tomography (PET) imaging probes for Alzheimer's disease and autism spectrum disorder will be developed thanks to two grants from the National Institute on Aging and the National Institute of Mental Health. These probes are intended to show real-time brain activity that occurs as the disease progresses.
The grants will provide a total of $9.6 million over five years to support multidisciplinary teams working together in the Department of Radiology and Imaging Sciences of the Emory University School of Medicine's new Positron Emission Tomography Imaging Center and the Radiopharmaceutical Discovery Program. Pharmacology and Chemical Biology, Neurology, and Psychiatry are some of the departments that collaborate.
According to principal investigator Steven Liang, PhD, an associate professor in the Department of Radiology and Imaging Sciences, "We are truly honored to receive this federal support to advance our understanding of Alzheimer's disease and autism spectrum disorder by using next-generation PET imaging technologies.
According to principal investigator Steven Liang, PhD, an associate professor in the Department of Radiology and Imaging Sciences, "We are truly honored to receive this federal support to advance our understanding of Alzheimer's disease and autism spectrum disorder by using next-generation PET imaging technologies.
"We can more rapidly and efficiently progress clinical exploration and drug discovery to assist the millions of people living with Alzheimer's disease and other forms of dementia by working with outstanding Emory faculty members in translational brain research.
Read more: A listeria outbreak 2022 story you never knew
The imaging probes project is a multidisciplinary partnership with co-investigators Stephen F. Traynelis, PhD, professor, and Hongjie Yuan, MD, PhD, associate professor, both from the Department of Pharmacology and Chemical Biology at the Emory School of Medicine, as well as Allan Levey, MD, PhD, Robert W. Woodruff Professor of Neurology, Goizueta Foundation Endowed Chair Larry Young, PhD, professor of psychiatry and behavioral sciences and director of the Center for Translational Social Neuroscience at the Emory National Primate Research Center, is working on an autism-related study with other centers and departments.
The imaging probes project is a multidisciplinary partnership with co-investigators Stephen F. Traynelis, PhD, professor, and Hongjie Yuan, MD, PhD, associate professor, both from the Department of Pharmacology and Chemical Biology at the Emory School of Medicine, as well as Allan Levey, MD, PhD, Robert W. Woodruff Professor of Neurology, Goizueta Foundation Endowed Chair Larry Young, PhD, professor of psychiatry and behavioral sciences and director of the Center for Translational Social Neuroscience at the Emory National Primate Research Center, is working on an autism-related study with other centers and departments.
Read more: Cancer risk is raised by anti ageing medications
According to Elizabeth Krupinski, PhD, professor and vice chair for research at the Department of Radiology and Imaging Sciences, "This work has the potential to change the game." "Dr. Liang's initiatives focus on radiochemistry, drug development, and translational PET imaging research in a variety of species, including rats, nonhuman primates, and humans. We are thrilled to encourage cross-departmental connections to bring fundamental science findings to people and to promote this successful collaboration, which is the product of our Team Science strategy.
From Hope to Significant Impact
According to Elizabeth Krupinski, PhD, professor and vice chair for research at the Department of Radiology and Imaging Sciences, "This work has the potential to change the game." "Dr. Liang's initiatives focus on radiochemistry, drug development, and translational PET imaging research in a variety of species, including rats, nonhuman primates, and humans. We are thrilled to encourage cross-departmental connections to bring fundamental science findings to people and to promote this successful collaboration, which is the product of our Team Science strategy.
In addition to creating imaging agents to identify recurrent prostate cancer and leading clinical trials for the radiotracer to aid in clinical decision-making for patients with recurring prostate cancer, this record also includes developing the first imaging diagnostics for prostate cancer.
This next wave of discovery, in Saindane's opinion, is similarly promising. The cutting-edge PET imaging methods created by Dr. Liang and his research group have the potential to significantly improve our comprehension of these debilitating neurodegenerative and neurodevelopmental illnesses. We want to enhance these cutting-edge imaging techniques so they may be applied to studies testing cutting-edge neurotherapeutics
0 Comments